Why the study?
Hypertrophic cardiomyopathy linked to damaging ALPK3 variants is a recent discovery with only a small number of patients described to date.
This report highlights the significant variability in symptoms and age of onset among patients with hypertrophic cardiomyopathy associated with ALPK3 variants.
Answers are grounded in this paper and cite their sources.
Adds ALPK3 cases with variable HCM onset; leaves open genotype-phenotype correlations and natural history.
Hypertrophic cardiomyopathy associated with damaging variants in the ALPK3 gene is a fairly recent discovery, and only a small number of patients have been described thus far. Here we present two additional patients with hypertrophic cardiomyopathy caused by biallelic variants in ALPK3. Genetic investigation was performed using a targeted gene panel consisting of known cardiomyopathy-associated genes and whole exome sequencing. The patients showed a large difference in the age of onset, and both presented with extracardiac features that are often seen in ALPK3 patients. The patient with the later onset showed milder extracardiac symptoms, such as decreased muscle tone and distal muscular dystrophy, but had fast progression of cardiac complications leading to the need of heart transplantation. This study further elucidates the variability of both symptoms and age of onset among these patients.
No takes yet. Share an insight, caveat, or question.
Jörholt et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: